Table 2.
Virological Primary Outcomes of Patients With or Without M184V/I Mutations Archived in Overall Population
| Primary Outcomes (Overall Population) | |||
|---|---|---|---|
| Outcomes | Without M184V/I (N = 1489) | With M184V/I (N = 137) | P value |
| VF | 17 (1.21%) | 4 (3%) | .09 |
| - 2x HIV-RNA >50 copies/mL | 10 | 1 | — |
| - 1x HIV-RNA >50 copies/mL + ABC/3TC/DTG stop | 7 | 3 | — |
| Treatment (ABC/3TC/DTG) discontinued for reasons other than VF | 232 (15.6%) | 14 (10.2%) | .12 |
| VB | |||
| - at least 1 VB during ABC/3TC/DTG treatment | 63 (4.2%) | 12 (8.8%) | .03 |
| - mean copies/ml (95% CI) | 181 (92–269) | 267 (-28–563) | .55 |
| Incidence of VF per 1000 person-years | 13.6 (8.4–21.8) | 29.8 (11.2–79.4) | .09 |
Abbreviations: ABC/3TC/DTG, abacavir/lamivudine/dolutegravir; CI, confidence interval; VB, virological blips; VF, virological failure.